Under a tenth of patients that would benefit from GLP-1 drugs including Wegovy are able to get them, caution the WHO as it issues its first recommendations on the medications.
Considering over a billion individuals worldwide now classified as obese, it is advocating for more widespread and fairer access to these injectable treatments.
Based on forecasts, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"The new guidelines acknowledges that excess weight is a long-term condition that can be managed with thorough and ongoing support," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are significant barriers to widespread availability to the injections that can aid individuals in losing significant body mass, notes the body.
Skinny Jab Supply Crisis
Even under the present most favorable case, the supply of such drugs could only cover around 100 million people – less than 10% of those who need them, as stated by the WHO.
The guideline calls on countries and companies to expand access, through strategies including licensing agreements.
Exclusive production rights on the active ingredient – the core component of a leading brand – is scheduled to end in a number of countries in 2026.
The Way Weight-Loss Injections Operate
These medications replicate a biological compound to delay gastric emptying, curb appetite and boost feelings of fullness so people consume fewer calories.
People usually see weight reduction in the initial weeks of beginning the once-weekly jabs.
Studies indicates people may see weight return after a year of stopping the treatment, when their typical appetite come back.
To be carrying excess weight raises your likelihood for developing diseases, such as diabetes, heart disease, brain attack, and specific cancers.
Obesity concerns people in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, according to the WHO.
